Payment overview · 2025
General Payments
$369.75
6 reported records · 4 companies
Healthcare provider profile · identity verified
Sama Alvi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARTFORD, CT · NPI 1437462991
Verified facts
What the public records show
CMS Open Payments records show Sama Alvi, M.D. received $369.75 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xifaxan.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $153.82 | 41.6% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $141.70 | 38.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.25 | 13.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.98 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $369.75 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $153.82 | 2 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $141.70 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 456 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 50 |
| Trazodone Hcl | Trazodone Hcl | 283 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 269 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 33 |
| Furosemide | Furosemide | 207 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 31 |
| Gabapentin | Gabapentin | 167 | 22 |
| Potassium Chloride | Potassium Chloride | 145 | 17 |
| Mirtazapine | Mirtazapine | 137 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 17 |
| Losartan Potassium | Losartan Potassium | 92 | 16 |
| Metformin Hcl | Metformin Hcl | 91 | 14 |
| Buspirone Hcl | Buspirone Hcl | 85 | 11 |
| Sertraline Hcl | Sertraline Hcl | 84 | 12 |
| Xarelto | Rivaroxaban | 82 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 11 |
| Donepezil Hcl | Donepezil Hcl | 69 | suppressed |
| Lisinopril | Lisinopril | 67 | suppressed |
| Risperidone | Risperidone | 62 | 12 |
| Carvedilol | Carvedilol | 61 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | 15 |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Famotidine | Famotidine | 51 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Torsemide | Torsemide | 40 | 11 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 37 | 34 |
| Acetic Acid | Acetic Acid | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 17 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Timolol Maleate | Timolol Maleate | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Risperidone Odt | Risperidone | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 11 |
| Galantamine Er | Galantamine Hbr | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Omeprazole | Omeprazole | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Protonix | Pantoprazole Sodium | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Liraglutide | Liraglutide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $369.75 · 6 records | Otsuka America Pharmaceutical, Inc. | INGREZZA, REXULTI, TERLIVAZ, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xifaxan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error